DNA vs SLDB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

DNA

42.9
AI Score
VS
DNA Wins

SLDB

38.0
AI Score

Investment Advisor Scores

DNA

43score
Recommendation
HOLD

SLDB

38score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric DNA SLDB Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -28.6% -100.0% DNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 42.9/100 38.0/100 DNA
Profit Margin -192.0% 0.0% SLDB
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY DNA

Relative Price Performance (Last 90 Days)

DNA 1M: +1.9% · 3M: +66.6% SLDB 1M: +6.9% · 3M: -20.9%

Current Technical Phase

DNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (16.1% over 20 days), RSI 54

RSI (14): 54.4 · Price: $12.01

SLDB

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 57.6 · Price: $7.17

Fundamentals Snapshot

Metric DNA SLDB
Market Cap — —
Forward P/E -4.1 -4.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.3% -1.0%
Gross Margin 0.7% —
Operating Margin -1.6% 0.0%
EPS -4.24 -1.76
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.